{"entity":{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","aka":[],"tldr":"Adding the anti-GD2 antibody to relapse chemotherapy doubled response rates in relapsed neuroblastoma, and the idea is now moving into first-line induction.","summary":"Adding the anti-GD2 antibody dinutuximab to irinotecan and temozolomide chemotherapy is a combination pairing for relapsed neuroblastoma that has become the standard treatment at first relapse. Chemotherapy releases antigen and depletes suppressive cells while the antibody directs antibody-dependent cellular cytotoxicity against GD2, a disialoganglioside that chemotherapy does not downregulate. In the randomised phase 2 ANBL1221 trial the irinotecan-temozolomide-dinutuximab arm produced far more responses than the temsirolimus comparator, and a confirmatory expansion supported the result. The concept is now moving into first-line induction in ANBL17P1, which tests dinutuximab during induction, and naxitamab combined with chemotherapy shows a similar pattern.","asOf":"2026-09-07","links":[{"label":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (Lancet Oncology 2017)","url":"https://doi.org/10.1016/S1470-2045(17)30355-8"}],"tags":[],"related":[],"cancers":["neuroblastoma","neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":["gd2"],"drugs":["dinutuximab","naxitamab","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"dinutuximab","b":"temozolomide","rationale":"Chemotherapy releases antigen and depletes suppressive cells while the antibody directs ADCC; GD2 is not downregulated by chemotherapy.","evidence":"Randomised phase 2 (ANBL1221) and confirmatory expansion.","pairingType":"combination"},"route":"/pairings/anti-gd2-plus-chemo-relapse/","neighbours":{"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"target":[{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/"}],"drug":[{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"},{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}